DB:OT1A

Stock Analysis Report

Executive Summary

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States.


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Orchard Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OT1A has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0.9%

OT1A

1.0%

DE Biotechs

2.0%

DE Market


1 Year Return

n/a

OT1A

6.8%

DE Biotechs

15.1%

DE Market

Return vs Industry: Insufficient data to determine how OT1A performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how OT1A performed against the German Market.


Shareholder returns

OT1AIndustryMarket
7 Day0.9%1.0%2.0%
30 Day-17.8%-1.2%1.0%
90 Day24.0%7.4%3.8%
1 Yearn/a7.1%6.8%18.6%15.1%
3 Yearn/a48.3%46.6%16.8%6.6%
5 Yearn/a11.4%9.0%23.7%6.7%

Price Volatility Vs. Market

How volatile is Orchard Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Orchard Therapeutics undervalued compared to its fair value and its price relative to the market?

3.58x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OT1A's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OT1A's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OT1A is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OT1A is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OT1A's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OT1A is overvalued based on its PB Ratio (3.6x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Orchard Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

25.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OT1A is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OT1A is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OT1A is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OT1A's revenue (66.9% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: OT1A's revenue (66.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OT1A is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Orchard Therapeutics performed over the past 5 years?

34.6%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: OT1A is currently unprofitable.

Growing Profit Margin: OT1A is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if OT1A's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare OT1A's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OT1A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: OT1A has a negative Return on Equity (-42.11%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Orchard Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: OT1A's short term assets ($393.5M) exceed its short term liabilities ($44.3M).

Long Term Liabilities: OT1A's short term assets ($393.5M) exceed its long term liabilities ($30.7M).


Debt to Equity History and Analysis

Debt Level: OT1A's debt to equity ratio (7.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if OT1A's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: OT1A has a low level of unsold assets or inventory.

Debt Coverage by Assets: OT1A's debt is covered by short term assets (assets are 16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OT1A has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OT1A has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of -65.5% each year.


Next Steps

Dividend

What is Orchard Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate OT1A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OT1A's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OT1A's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OT1A's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OT1A's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Mark Rothera (56yo)

2.5yrs

Tenure

Mr. Mark A. Rothera has been Chief Executive Officer, President, and Director of Orchard Therapeutics Limited since August 14, 2017. Mr. Rothera serves as Consultant of PTC Therapeutics, Inc. since August  ...


Leadership Team

NamePositionTenureCompensationOwnership
Mark Rothera
CEO, President & Director2.5yrsno data0.20% $2.3m
Frank Thomas
COO, CFO & Chief Business Officer2.1yrsno data0.030% $342.1k
Ran Zheng
Chief Technical Officer0.9yrsno datano data
Bobby Gaspar
MD, Chief Scientific Officer0yrsno data0.80% $9.0m
Renee Leck
Director of Investor Relations0yrsno datano data
John Ilett
General Counsel & Company Secretary0yrsno datano data
Kathryn Payne
Senior Vice President of Corporate Communications & External Affairs0yrsno datano data
John Cerio
Global Head of Human Resources & Senior VP0yrsno datano data
Andrea Spezzi
Chief Medical Officer0yrsno datano data
Anne Dupraz-Poiseau
Chief Regulatory Officer0yrsno datano data

2.3yrs

Average Tenure

55yo

Average Age

Experienced Management: OT1A's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mark Rothera
CEO, President & Director2.5yrsno data0.20% $2.3m
Bobby Gaspar
MD, Chief Scientific Officer0yrsno data0.80% $9.0m
James Geraghty
Chairman of the Board1.8yrsno data0.092% $1.0m
Charles Rowland
Director1.6yrsno data0.025% $286.0k
Donald Kohn
Member of Scientific Advisory Board0yrsno datano data
Alessandra Biffi
Member of Scientific Advisory Board0yrsno datano data
Brian Bigger
Member of Scientific Advisory Board0yrsno datano data
Simon Jones
Member of Scientific Advisory Board0yrsno datano data
Adrian Thrasher
Member of Scientific Advisory Board0yrsno datano data
David Williams
Member of Scientific Advisory Board0yrsno datano data

1.8yrs

Average Tenure

58.5yo

Average Age

Experienced Board: OT1A's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 792.2%.


Top Shareholders

Company Information

Orchard Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Orchard Therapeutics plc
  • Ticker: OT1A
  • Exchange: DB
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.216b
  • Listing Market Cap: US$1.122b
  • Shares outstanding: 96.52m
  • Website: https://www.orchard-tx.com

Number of Employees


Location

  • Orchard Therapeutics plc
  • 108 Cannon Street
  • London
  • Greater London
  • EC4N 6EU
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ORTXNasdaqGS (Nasdaq Global Select)YesADSUSUSDOct 2018
OT1ADB (Deutsche Boerse AG)YesADSDEEUROct 2018

Biography

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type MPS-IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is based in London, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 23:08
End of Day Share Price2020/02/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.